Compare MIRM & STEP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MIRM | STEP |
|---|---|---|
| Founded | 2018 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance/Investors Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.4B | 5.0B |
| IPO Year | 2019 | 2020 |
| Metric | MIRM | STEP |
|---|---|---|
| Price | $86.88 | $47.18 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 12 | 7 |
| Target Price | ★ $114.67 | $78.43 |
| AVG Volume (30 Days) | 763.1K | ★ 1.5M |
| Earning Date | 05-06-2026 | 02-05-2026 |
| Dividend Yield | N/A | ★ 3.25% |
| EPS Growth | ★ 74.59 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $19,138,000.00 | ★ $1,174,830,000.00 |
| Revenue This Year | $26.22 | N/A |
| Revenue Next Year | $21.77 | $28.61 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 65.09 |
| 52 Week Low | $36.88 | $40.27 |
| 52 Week High | $109.28 | $77.80 |
| Indicator | MIRM | STEP |
|---|---|---|
| Relative Strength Index (RSI) | 40.71 | 43.21 |
| Support Level | $85.76 | $40.58 |
| Resistance Level | $96.65 | $63.60 |
| Average True Range (ATR) | 3.90 | 1.80 |
| MACD | -0.38 | 1.00 |
| Stochastic Oscillator | 16.52 | 75.44 |
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.
StepStone Group Inc operates as a fully integrated private markets solution provider. The company provides customized investment solutions and advisory and data services. It provides investment solutions in the areas of private equity, real estate, private debt, and infrastructure and real assets. The company consists of a single operating segment and a single reportable segment for accounting and financial reporting purposes.